862 related articles for article (PubMed ID: 25972237)
1. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
2. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
[TBL] [Abstract][Full Text] [Related]
4. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
5. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
[TBL] [Abstract][Full Text] [Related]
6. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
7. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
9. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.
Schneider JS; Aras R; Williams CK; Koprich JB; Brotchie JM; Singh V
Sci Rep; 2019 Jun; 9(1):8362. PubMed ID: 31182727
[TBL] [Abstract][Full Text] [Related]
10. Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.
Howson PA; Johnston TH; Ravenscroft P; Hill MP; Su J; Brotchie JM; Koprich JB
J Pharmacol Exp Ther; 2019 Jun; 369(3):364-374. PubMed ID: 30918068
[TBL] [Abstract][Full Text] [Related]
11. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
[TBL] [Abstract][Full Text] [Related]
12. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
[TBL] [Abstract][Full Text] [Related]
15. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
16. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
Van der Perren A; Toelen J; Casteels C; Macchi F; Van Rompuy AS; Sarre S; Casadei N; Nuber S; Himmelreich U; Osorio Garcia MI; Michotte Y; D'Hooge R; Bormans G; Van Laere K; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
Neurobiol Aging; 2015 Mar; 36(3):1543-58. PubMed ID: 25599874
[TBL] [Abstract][Full Text] [Related]
18. Viral mimetic priming enhances α-synuclein-induced degeneration: Implications for Parkinson's disease.
Olsen LK; Cairns AG; Ådén J; Moriarty N; Cabre S; Alamilla VR; Almqvist F; Dowd E; McKernan DP
Brain Behav Immun; 2019 Aug; 80():525-535. PubMed ID: 31029796
[TBL] [Abstract][Full Text] [Related]
19. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
20. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.
Musacchio T; Rebenstorff M; Fluri F; Brotchie JM; Volkmann J; Koprich JB; Ip CW
Ann Neurol; 2017 Jun; 81(6):825-836. PubMed ID: 28470693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
